AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01486121 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Therapy strategy
Description: Sedation \& mechanical ventilation
Study NCT01500876 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4D-CT pre-treatment scan
Description: Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
Study NCT00119015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00119015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Study NCT00119015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate
Study NCT00119015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone propionate
Study NCT02670057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transnasal SPG block
Study NCT03666585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobile application actuated rehabilitation exercise guidance
Description: Mobile applications (also known as mobile apps) are software programs developed for mobile devices such as smartphones and tablets, to teach full function following injury and involves restoring strength, flexibility, endurance, and power.
Study NCT03666585 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation exercise guidance
Description: the teach to practice full function following injury and involves restoring strength, flexibility, endurance, and power. It is achieved through various exercises and drills
Study NCT01607645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT01607645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin
Description: Given IV
Study NCT01607645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT02327130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Isomark Canary™
Description: Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.
Study NCT04772105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2.5mg of BAT5906
Description: Specification: 2.5mg of BAT5906
Study NCT04772105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4.0mg of BAT5906
Description: Specification: 4.0mg of BAT5906
Study NCT01647737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MighTeaFlow
Description: 4-6 times daily
Study NCT01870856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Per participant's habitual prescription
Study NCT01870856 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A contact lenses
Description: Silicone hydrogel single vision contact lenses
Study NCT01870856 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Etafilcon A contact lenses
Description: Hydrogel single vision contact lenses
Study NCT01793194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression Stockings
Description: 20-30mmg Hg maternity pantyhose compression stockings
Study NCT03435081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT03435081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study NCT03435081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT04325828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240 mg (4\*60-mg tablets) will be administered orally once daily with or without food.
Study NCT04325828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH Agonist
Description: A stable regimen of goserelin 3.6 mg will be administered as a GnRH agonist.
Study NCT01647737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol
Description: 4-6 times daily
Study NCT06321692 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of blood levels of biomarkers of cardiac damage
Description: Evaluation of ultra-sensitive troponin I, BNP, NT-proBNP, and ST2 in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome
Study NCT02153502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
Description: AVP-786 capsules administered twice a day over a 10-week period
Study NCT02153502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered twice a day over a 10-week period
Study NCT00977847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Portals for collecting Family History data
Description: Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
Study NCT01900002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01900002 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01900002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO
Study NCT01900002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT01900002 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given IA
Study NCT00097981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
Study NCT00097981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
Study NCT00097981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
Study NCT00097981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
Study NCT00097981 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL
Description: DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
Study NCT00888238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
Study NCT00888238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
Study NCT00903279 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
Study NCT00903279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Altabax (retapamulin)
Description: Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
Study NCT01359566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen placarbil 15 mg BID
Description: arbaclofen placarbil 15 mg BID
Study NCT01359566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
Study NCT01359566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen placarbil 30 mg BID
Description: arbaclofen placarbil 30 mg BID
Study NCT01359566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen placarbil 45 mg BID
Description: arbaclofen placarbil 45 mg BID
Study NCT03239509 — intervention group
Intervention type: PROCEDURE
Intervention: bioprosthesis implantation between 2000-2015
Description: Implantation of a bioprosthesis in aortic position with cardiopulmonary bypass
Study NCT03239509 — intervention group
Intervention type: PROCEDURE
Intervention: mechanical prosthesis implantation between 2000-2015
Description: Implantation of a mechanical prosthesis in aortic position with cardiopulmonary bypass
Study NCT02751398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Study NCT02751398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10mg
Description: Matching placebo for dapagliflozin 10 mg
Study NCT04019678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of Axillary dissection
Description: In Group 1 and 2: Axillary dissection won't be performed
Study NCT04019678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omission of Axillary dissection
Description: In Group 1 and 2: Axillary dissection won't be performed
Study NCT00769041 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400mg
Study NCT00769041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 100mg single dose
Study NCT00769041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 800mg single dose
Study NCT00769041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: single dose
Study NCT02879877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7858
Study NCT02879877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02075437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeling and Body Investigators with Functional Abdominal Pain
Description: Investigator's ten session intervention trains children to be Feeling and Body Investigators. Half of the sessions will be done in clinic and half at home via web-camera to facilitate generalization. During the treatment child/caregiver dyads will 1) gather body clues (Learn), 2) investigate (Experience: perform interoceptive mystery missions to explore a body sensation), 3) organize body clues (Contextualize: recall other context that evoke similar sensations), and 4) go on increasingly daring missions (Challenge: decrease avoidance and safety behaviors).~If successful, young children with FAP who complete the FBI early intervention will learn to experience changes in the viscera as fun and fascinating, rather than scary, and will develop new capacities for pain management, adaptive functioning, and emotion regulation.
Study NCT02075437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Strategies
Description: 1. identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis:~2. adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children;~3. incorporate caregivers as role models and facilitators based on attachment research.
Study NCT03002779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678 corresponding to a radioactivity dose.
Study NCT04562662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mediVR KAGURA
Description: Approximately 20 min mediVR KAGURA-guided rehabilitation
Study NCT03619746 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POCUS Educational Intervention
Description: Midway through the study, all Pediatric Emergency Attendings and Fellows at Jacobi Medical Center will receive an educational session that describes how to properly perform a soft tissue examination using point-of-care ultrasound to differentiate between cellulitis and local allergic reaction.
Study NCT03743753 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The intervention is the educational session, which is a one-on-one session delivered by a research assistant using a visual aide on an iPad (power point presentation). The session is specifically tailored to the method of breast reconstruction (autologous or alloplastic) the patient will undergo and reviews the basics of their reconstruction, explains the normal in-hospital course and post-operative recovery, reviews potential complications and provides advice from previous breast reconstruction patients.
Study NCT02441309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifamurtide
Study NCT02441309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT01950611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute promyelocytic leukemia
Study NCT04350086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Dexmedetomidine
Description: Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 µg / kg / h, with dose adjustment according to the sedation score and tolerance.
Study NCT00724321 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: iloprost
Description: A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
Study NCT03483064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interferential current
Description: interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold
Study NCT03061734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Acetaminophen
Description: Naltrexone plus acetaminophen
Study NCT03061734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Acetaminophen-High Dose
Description: Naltrexon (high dose) plus acetaminophen
Study NCT03061734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Alone (regular dose)
Description: Naltrexone Alone plus Placebo
Study NCT03061734 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Alone
Description: Acetaminophen Alone plus Placebo
Study NCT03061734 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Two Placebo capsules
Study NCT04473170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)
Description: SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.
Study NCT04473170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 standard care
Description: UAE National Guidelines for Clinical Management and Treatment of COVID-19.
Study NCT02726425 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Self Management Medical Group Visits
Description: The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians \& peer leaders lasting \~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
Study NCT02726425 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self Management Medical Group Visits
Description: The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians \& peer leaders lasting \~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
Study NCT00584922 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopy in group I (all patients)
Description: Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
Study NCT03643978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: The decision aids aim to inform the patients about the diagnosis and the treatment options. They aim to help the patient prioritize and make an informed decision.
Study NCT02478957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA101
Description: 40 mg PA101 administered via inhalation three times daily for 6 weeks
Study NCT02478957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo administered via inhalation three times daily for 6 weeks
Study NCT02682680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam 3.75 g daily for 24 weeks
Study NCT02682680 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily for 24 weeks
Study NCT00604877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise
Description: 3 times per week for 6 months, with target of 45 minutes at 60-70% heart rate range
Study NCT00604877 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching/ROM
Description: 3 times per week for 6 months, passive and active stretching and range of motion (ROM) exercises for the upper and lower extremities
Study NCT02355431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: tablets to be administered by mouth once daily at dose selected from safety run-in phase
Study NCT02355431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg tablets administered by mouth once daily at total daily dose of 150 mg
Study NCT02355431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: 150 mg tablets administered by mouth once daily at total daily dose of 150 mg
Study NCT02355431 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
Study NCT04347642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical port placement
Description: The port will be inserted in the midline at the level of the umbilicus.
Study NCT04347642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraumbilical port placement
Description: The port will be inserted 3-4cm laterally to the midline at the level of the umbilicus.
Study NCT01653353 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer physician-applied recommendation to the physicians
Description: The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
Study NCT03902496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT-6 Questionnaire
Description: Headache Impact Test
Study NCT03902496 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: HIT-6 Questionnaire
Description: Headache Impact Test
Study NCT03902496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avulux Spectacles
Description: Avulux™ Optical Filter in the Form of Spectacle Lenses
Study NCT03902496 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Spectacles
Description: Sham
Study NCT02683837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Study NCT02683837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil